Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

  • Revenue in CHF (TTM)63.28bn
  • Net income in CHF12.42bn
  • Incorporated1966
  • Employees103.61k
  • Location
    Roche Holding AGGrenzacherstrasse 124BASEL 4058SwitzerlandCHE
  • Phone+41 9 732354295
  • Websitehttps://www.roche.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ROG:SWX since
Good Therapeutics IncAnnounced07 Sep 202207 Sep 2022Announced-19.41%250.00m
Data delayed at least 15 minutes, as of Mar 31 2023 12:25 BST.

Institutional shareholders

7.28%Per cent of shares held by top holders
HolderShares% Held
APG Asset Management NVas of 31 Dec 20211.43m1.34%
Canada Pension Plan Investment Boardas of 31 Mar 20221.29m1.21%
RBC Global Asset Management (UK) Ltd.as of 31 Dec 2021983.99k0.92%
The Vanguard Group, Inc.as of 03 Mar 2023891.95k0.84%
Credit Suisse Asset Management (Schweiz) AGas of 28 Feb 2023811.33k0.76%
UBS Asset Management Switzerland AGas of 28 Feb 2023752.79k0.71%
BlackRock Fund Advisorsas of 01 Mar 2023681.56k0.64%
Ignis Investment Services Ltd.as of 31 Jul 2022492.84k0.46%
BlackRock Advisors (UK) Ltd.as of 01 Mar 2023225.82k0.21%
Vontobel Asset Management AGas of 28 Feb 2023210.78k0.20%
More ▼
Data from 30 Jun 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.